Hormonal
Intensive blood pressure control (Systolic < 120 mmHg) in Type 2 Diabetes does not reduce major cardiovascular events compared to standard control (< 140 mmHg) and increases adverse events like hypotension and renal failure.
For Type 2 Diabetics with high blood pressure, aiming for a standard target (e.g., <140/90 mmHg) is likely sufficient for preventing major heart events and avoids the risks of side effects like fainting or kidney stress associated with very aggressive lowering (<120 mmHg). Consult your doctor for a personalized target based on age and comorbidities.
After 4.7 years of follow-up, the group with intensive BP control did not have a reduction in deadly and nonfatal most important CV occasions as compared to the standard BP control group... In addition, the intensive BP group had elevated unfavorable activities which include hypotension, syncope, bradycardia or arrhythmia, hyperkalemia, angioedema and renal failure.
Why this rating
Based on the large ACCORD-BP randomized controlled trial.
Source
review on epidemiology, biochemical characteristics, treatment suggestions, and continued studies on diabetes and cardiovascular disease
Rajni Yadav · International Journal of Health Sciences · 2022
DOI 10.53730/ijhs.v6ns3.7084
More from this paper
- Tight glycemic control (HbA1c ≤ 6.5%) in Type 2 Diabetes does not significantly reduce major cardiovascular events or all-cause mortality compared to standard control, and may increase mortality and hypoglycemia risk.Strong
- Modest weight loss (5%) in Type 2 Diabetes improves cardiovascular risk factors (lipids, glucose) but evidence for reducing actual cardiovascular mortality or events is mixed and inconclusive.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →